MIAMI, Feb. 13, 2004 (PRIMEZONE) -- Stockwire Research Group Inc. today adds ImClone Systems Inc. (Nasdaq:IMCL) to its Outperform List as the Company late yesterday received approval from the FDA for its colon cancer therapy drug Erbitux.
Erbitux, formerly known as IMC-C225, is an investigational IgG1 therapeutic monoclonal antibody that inhibits stimulation of the Epidermal Growth Factor (EGF) receptor upon which certain solid tumors depend in order to grow. Erbitux has been shown in several early stage clinical trials to have an acceptable safety profile, to be well tolerated and, when administered alone or in combination with radiation therapy or chemotherapy, to cause tumor reduction in certain cases.
To view the full report, go to www.stockwire.com.
Stockwire.com is an online financial destination where investors can go to research new investment ideas. We are focused on finding emerging growth companies that do not necessarily have widespread analyst coverage on Wall Street. The site also provides investors with full coverage of quotes, charts, and news for all publicly listed stocks in the U.S.
If you'd like a complete list of all of our profiled companies, visit: www.stockwire.com.
Investors are advised that this analysis is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. This report does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this information. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Past performance is no guarantee of future results. Any opinions expressed herein are statements of our judgment as of the date of publication and are subject to change without notice. Reproduction without written permission is prohibited. Stockwire Research Group, Inc. has not been compensated in any form for the release of this press wire or for the creation and distribution of the IMCL research report.